

# PRODUCT INFORMATION



## Eliglustat-d<sub>15</sub> (tartrate)

Item No. 30167

**Formal Name:** N-[(1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]-octanamide-2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-d<sub>15</sub>, (2R,3R)-2,3-dihydroxybutanedioate

**MF:** C<sub>23</sub>H<sub>21</sub>D<sub>15</sub>N<sub>2</sub>O<sub>4</sub> • C<sub>4</sub>H<sub>6</sub>O<sub>6</sub>

**FW:** 569.7


**Chemical Purity:** ≥98% (Eliglustat)

**Deuterium Incorporation:** ≥99% deuterated forms (d<sub>1</sub>-d<sub>15</sub>); ≤1% d<sub>0</sub>

**Supplied as:** A solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Eliglustat-d<sub>15</sub> is intended for use as an internal standard for the quantification of eliglustat (Item No. 21487) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Eliglustat-d<sub>15</sub> is supplied as a solid. A stock solution may be made by dissolving the eliglustat-d<sub>15</sub> in the solvent of choice, which should be purged with an inert gas. Eliglustat-d<sub>15</sub> is soluble in methanol and DMSO.

### Description

Eliglustat is an inhibitor of glucosylceramide synthase (IC<sub>50</sub> = 40 nM for inhibition of glucosylceramide production in K562 cells).<sup>1</sup> It is selective for glucosylceramide synthase over α-glucosidase I and II, α-1,6-glucosidase, lysosomal glucocerebrosidase, non-lysosomal glucosylceramidase, sucrase, and maltase (IC<sub>50</sub>s = >10 μM for all). It decreases cell surface levels of the gangliosides GM<sub>1</sub> and GM<sub>3</sub> in K562 and B16/F10 cells with IC<sub>50</sub> values of 24 and 29 nM, respectively. Eliglustat (150 mg/kg per day) decreases glucosylceramide levels in the liver and lungs of D409V/null mice, a model of Gaucher disease. Formulations containing eliglustat have been used in the treatment of type 1 Gaucher disease.

### Reference

1. McEachern, K.A., Fung, J., Komarnitsky, S., *et al.* A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. *Mol. Genet. Metab.* **91**(3), 259-267 (2007).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/27/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM